C57Bl/KsJ-db/db-Apc min/+ mice exhibit an increased incidence of intestinal neoplasms

International Journal of Molecular Sciences

Volumn 12, Issue 11, 2011, Pages 8133-8145

  Hata, Kazuya ^a,b   Kubota, Masaya ^a   Shimizu, Masahito ^a   Moriwaki, Hisataka ^a   Kuno, Toshiya ^a   Tanaka, Takuji ^a,c,d   Hara, Akira ^a   Hirose, Yoshinobu ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kamiishidu Division   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d Cancer Research and Prevention   (Japan)

Author keywords

Animal model; C57BL 6J Apc min +; C57Bl KsJ db db; Colon carcinogenesis; Type 2 diabetes mellitus

Indexed keywords

APC PROTEIN; BETA CATENIN; CHOLESTEROL; GLUCOSE; INSULIN; INTERFERON REGULATORY FACTOR 1 RECEPTOR; RNA; SOMATOMEDIN B; SOMATOMEDIN C; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; IGF2 PROTEIN, MOUSE; INSULIN-LIKE GROWTH FACTOR-1, MOUSE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BREEDING; C57BL KSJ MOUSE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHOLESTEROL BLOOD LEVEL; COLON TUMOR; COLORECTAL CANCER; CONTROLLED STUDY; DIABETIC PATIENT; FAMILIAL COLON POLYPOSIS; FEMALE; GASTROINTESTINAL TRACT; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERINSULINEMIA; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INTESTINE ADENOMA; INTESTINE TUMOR; MALE; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; STRAIN DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; COLORECTAL NEOPLASMS; COMPLICATION; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; RISK FACTOR;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; COLORECTAL NEOPLASMS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FEMALE; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; RISK FACTORS; RNA, MESSENGER; TRIGLYCERIDES;

EID: 82255180784     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12118133     Document Type: Article

References (48)

1. Bergstrom, A.; Pisani, P.; Tenet, V.; Wolk, A.; Adami, H.O. Overweight as an avoidable cause of cancer in Europe. Int. J. Cancer 2001, 91, 421-430.
2. Murphy, T.K.; Calle, E.E.; Rodriguez, C.; Kahn, H.S.; Thun, M.J. Body mass index and colon cancer mortality in a large prospective study. Am. J. Epidemiol. 2000, 152, 847-854.
3. LeRoith, D.; Novosyadlyy, R.; Gallagher, E.J.; Lann, D.; Vijayakumar, A.; Yakar, S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp. Clin. Endocrinol. Diabetes 2008, 116, S4-S6.
4. Chang, C.K.; Ulrich, C.M. Hyperinsulinaemia and hyperglycaemia: Possible risk factors of colorectal cancer among diabetic patients. Diabetologia 2003, 46, 595-607.
5. Becker, S.; Dossus, L.; Kaaks, R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch. Physiol. Biochem. 2009, 115, 86-96.
6. Jalving, M.; Gietema, J.A.; Lefrandt, J.D.; de Jong, S.; Reyners, A.K.; Gans, R.O.; de Vries, E.G. Metformin: Taking away the candy for cancer? Eur. J. Cancer 2010, 46, 2369-2380.
7. Hosono, K.; Endo, H.; Takahashi, H.; Sugiyama, M.; Sakai, E.; Uchiyama, T.; Suzuki, K.; Iida, H.; Sakamoto, Y.; Yoneda, K.; Koide, T.; Tokoro, C.; Abe, Y.; Inamori, M.; Nakagama, H.; Nakajima, A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila) 2010, 3, 1077-1083.
8. Gallagher, E.J.; LeRoith, D. Insulin, insulin resistance, obesity, and cancer. Curr. Diabet. Rep. 2010, 10, 93-100.
9. Renehan, A.G.; Frystyk, J.; Flyvbjerg, A. Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol. Metab. 2006, 17, 328-336.
10. Shimizu, M.; Sakai, H.; Shirakami, Y.; Yasuda, Y.; Kubota, M.; Terakura, D.; Baba, A.; Ohno, T.; Hara, Y.; Tanaka, T.; Moriwaki, H. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice. Cancer Prev. Res. (Phila) 2011, 4, 396-403.
11. Hirose, Y.; Hata, K.; Kuno, T.; Yoshida, K.; Sakata, K.; Yamada, Y.; Tanaka, T.; Reddy, B.S.; Mori, H. Enhancement of development of azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Carcinogenesis 2004, 25, 821-825.
12. Hirose, Y.; Kuno, T.; Yamada, Y.; Sakata, K.; Katayama, M.; Yoshida, K.; Qiao, Z.; Hata, K.; Yoshimi, N.; Mori, H. Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 2003, 24, 107-111.
13. Hayashi, K.; Suzuki, R.; Miyamoto, S.; Shin-Ichiroh, Y.; Kohno, H.; Sugie, S.; Takashima, S.; Tanaka, T. Citrus auraptene suppresses azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db mice. Nutr. Cancer 2007, 58, 75-84.
14. Suzuki, R.; Kohno, H.; Yasui, Y.; Hata, K.; Sugie, S.; Miyamoto, S.; Sugawara, K.; Sumida, T.; Hirose, Y.; Tanaka, T. Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male db/db mice. Int. J. Cancer 2007, 120, 252-258.
15. Moser, A.R.; Pitot, H.C.; Dove, W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990, 247, 322-324.
16. Min/+ mice. Cancer Lett. 2006, 239, 123-128.
17. Min/+) mice. Cancer Res. 2002, 62, 6367-6370.
18. Corpet, D.E.; Pierre, F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur. J. Cancer 2005, 41, 1911-1922.
19. Dove, W.F.; Gould, K.A.; Luongo, C.; Moser, A.R.; Shoemaker, A.R. Emergent issues in the genetics of intestinal neoplasia. Cancer Surv. 1995, 25, 335-355.
20. DuBois, R.N.; Giardiello, F.M.; Smalley, W.E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am. 1996, 25, 773-791.
21. Gupta, R.A.; Dubois, R.N. Controversy: PPARgamma as a target for treatment of colorectal cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283, G266-G269.
22. Mutoh, M.; Niho, N.; Komiya, M.; Takahashi, M.; Ohtsubo, R.; Nakatogawa, K.; Ueda, K.; Sugimura, T.; Wakabayashi, K. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008, 29, 824-829.
23. Niho, N.; Takahashi, M.; Shoji, Y.; Takeuchi, Y.; Matsubara, S.; Sugimura, T.; Wakabayashi, K. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci. 2003, 94, 960-964.
24. Min/+) mice: Inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer 2006, 118, 25-34.
25. Singh, P.; Rubin, N. Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology 1993, 105, 1218-1237.
26. Belfiore, A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr. Pharm. Des. 2007, 13, 671-686.
27. Komninou, D.; Ayonote, A.; Richie, J.P., Jr.; Rigas, B. Insulin resistance and its contribution to colon carcinogenesis. Exp. Biol. Med. (Maywood) 2003, 228, 396-405.
28. Shimizu, M.; Shirakami, Y.; Iwasa, J.; Shiraki, M.; Yasuda, Y.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin. Cancer Res. 2009, 15, 3068-3075.
29. Lee, W.M.; Lu, S.; Medline, A.; Archer, M.C. Susceptibility of lean and obese Zucker rats to tumorigenesis induced by N-methyl-N-nitrosourea. Cancer Lett. 2001, 162, 155-160.
30. Weber, R.V.; Stein, D.E.; Scholes, J.; Kral, J.G. Obesity potentiates AOM-induced colon cancer. Dig. Dis. Sci. 2000, 45, 890-895.
31. Berster, J.M.; Goke, B. Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch. Physiol. Biochem. 2008, 114, 84-98.
32. Giouleme, O.; Diamantidis, M.D.; Katsaros, M.G. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J. Gastroenterol. 2011, 17, 444-448.
33. Seow, A.; Yuan, J.M.; Koh, W.P.; Lee, H.P.; Yu, M.C. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J. Natl. Cancer Inst. 2006, 98, 135-138.
34. Giovannucci, E. Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J. Nutr. 2001, 131, 3109S-3120S.
35. Tsugane, S.; Inoue, M. Insulin resistance and cancer: Epidemiological evidence. Cancer Sci. 2010, 101, 1073-1079.
36. Tran, T.T.; Medline, A.; Bruce, W.R. Insulin promotion of colon tumors in rats. Cancer Epidemiol. Biomarkers Prev. 1996, 5, 1013-1015.
37. Rosenzweig, S.A.; Atreya, H.S. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol. 2010, 80, 1115-1124.
38. Lee, P.D.; Giudice, L.C.; Conover, C.A.; Powell, D.R. Insulin-like growth factor binding protein-1: Recent findings and new directions. Proc. Soc. Exp. Biol. Med. 1997, 216, 319-357.
39. Suikkari, A.M.; Koivisto, V.A.; Rutanen, E.M.; Yki-Jarvinen, H.; Karonen, S.L.; Seppala, M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J. Clin. Endocrinol. Metab. 1988, 66, 266-272.
40. Mutoh, M.; Akasu, T.; Takahashi, M.; Niho, N.; Yoshida, T.; Sugimura, T.; Wakabayashi, K. Possible involvement of hyperlipidemia in increasing risk of colorectal tumor development in human familial adenomatous polyposis. Jpn. J. Clin. Oncol. 2006, 36, 166-171.
41. Sturmer, T.; Buring, J.E.; Lee, I.M.; Gaziano, J.M.; Glynn, R.J. Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 2391-2397.
42. Tabuchi, M.; Kitayama, J.; Nagawa, H. Hyperglycemia and hypertriglyceridemia may associate with the adenoma-carcinoma transition in colorectal epithelial cells. J. Gastroenterol. Hepatol. 2008, 23, 985-987.
43. Takahashi, H.; Yoneda, K.; Tomimoto, A.; Endo, H.; Fujisawa, T.; Iida, H.; Mawatari, H.; Nozaki, Y.; Ikeda, T.; Akiyama, T.; Yoneda, M.; Inamori, M.; Abe, Y.; Saito, S.; Nakajima, A.; Nakagama, H. Life style-related diseases of the digestive system: Colorectal cancer as a life style-related disease: From carcinogenesis to medical treatment. J. Pharmacol. Sci. 2007, 105, 129-132.
44. Niho, N.; Takahashi, M.; Kitamura, T.; Shoji, Y.; Itoh, M.; Noda, T.; Sugimura, T.; Wakabayashi, K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res. 2003, 63, 6090-6095.
45. Yasuda, Y.; Shimizu, M.; Shirakami, Y.; Sakai, H.; Kubota, M.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci. 2010, 101, 1701-1707.
46. Niho, N.; Mutoh, M.; Komiya, M.; Ohta, T.; Sugimura, T.; Wakabayashi, K. Improvement of hyperlipidemia by indomethacin in Min mice. Int. J. Cancer 2007, 121, 1665-1669.
47. Niho, N.; Mutoh, M.; Takahashi, M.; Tsutsumi, K.; Sugimura, T.; Wakabayashi, K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc. Natl. Acad. Sci. USA 2005, 102, 2970-2974.
48. Endo, H.; Hosono, K.; Uchiyama, T.; Sakai, E.; Sugiyama, M.; Takahashi, H.; Nakajima, N.; Wada, K.; Takeda, K.; Nakagama, H.; Nakajima, A. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011, 60, 1363-1371.